Predictors of a successful statin reattempt after an adverse reaction

Zhang, Huabing; Plutzky, Jorge; Ge, Wendong; Shubina, Maria; Turchin, Alexander

doi:10.1016/j.jacl.2018.02.005

Cited by 7 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rank order of the adverse events mentioned on WebMD was consistent with the rank order for spontaneous reporting data from the MHRA and FDA [ 44 ] and indeed previous observational studies [ 21 , 46 , 47 ] and social media studies [ 44 ]. Musculoskeletal events have been found to be the most predominant, accounting for 40–60% of all adverse events [ 19 , 21 , 33 ].…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media

et al. 2022

View full text Add to dashboard Cite

Introduction Statin discontinuation can have major negative health consequences. Studying the reasons for discontinuation can be challenging as traditional data collection methods have limitations. We propose an alternative approach using social media. Methods We used natural language processing and machine learning to extract mentions of discontinuation of statin therapy from an online health forum, WebMD ( http://www.webmd.com ). We then extracted data according to themes and identified key attributes of the people posting for themselves. Results We identified 2121 statin reviews that contained information on discontinuing at least one named statin. Sixty percent of people posting declared themselves as female and the most common age category was 55–64 years. Over half the people taking statins did so for < 6 months. By far the most common reason given (90%) was patient experience of adverse events, the most common of which were musculoskeletal and connective tissue disorders. The rank order of adverse events reported in WebMD was largely consistent with those reported to regulatory agencies in the US and UK. Data were available on age, sex, duration of statin use, and, in some instances, adverse event resolution and rechallenge. In some instances, details were presented on resolution of the adverse event and rechallenge. Conclusion Social media may provide data on the reasons for switching or discontinuation of a medication, as well as unique patient perspectives that may influence continuation of a medication. This information source may provide unique data for novel interventions to reduce medication discontinuation. Supplementary Information The online version contains supplementary material available at 10.1007/s40264-022-01212-0.

show abstract

Section: Discussionsupporting

confidence: 83%

“…Previous studies have suggested that rates of successful statin reattempt after an adverse event are high [ 47 ]. Our data on reattempt with the same statin do not suggest this to be the case; however, many people posting also reported switching statin medication or changing their dose, which may have led to better tolerability.…”

Section: Discussionmentioning

confidence: 99%

Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media

et al. 2022

View full text Add to dashboard Cite

show abstract

“…7,20 A study by Zhang et al showed that using a different statin was one of the factors associated with a successful statin rechallenge, ie, 24 months without discontinuation after the ADR. 36 Three different statins should be considered before proceeding to another LLT. 7 Another strategy included the use of an intermittent statin regimen.…”

Section: Discussionmentioning

confidence: 99%

“…Statin rechallenge after an ADR, ie, stopping and restarting any statin to check whether the symptoms are related to statin, is of importance and this can be performed using either the same (lower dose within the same intensity) or a different statin 7,20 . A study by Zhang et al showed that using a different statin was one of the factors associated with a successful statin rechallenge, ie, 24 months without discontinuation after the ADR 36 . Three different statins should be considered before proceeding to another LLT 7…”

Section: Discussionmentioning

confidence: 99%

Statin‐related adverse drug reactions in UK primary care consultations: A retrospective cohort study to evaluate the risk of cardiovascular events and all‐cause mortality

Insani

Whittlesea

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

To investigate the risk of cardiovascular disease (CVD) events and all-cause mortality in patients with statin-related adverse drug reaction (ADR) consultation in primary care and examine whether different treatments following the ADR affect subsequent outcomes.Methods: This was a retrospective cohort study of statin users between 2004 and 2019 using IQVIA Medical Research Data (formally known as the THIN database).Patients with statin-related ADR consultation were matched by propensity score(1:1) to statin users without ADR consultation based on demographics, comorbidities and concomitant medication. Cox proportional hazard regression was used to compare the risk of subsequent CVD event and all-cause mortality, stratified by history of CVD. In the secondary analysis among patients with statin-related ADR, treatment changes within a 1-year period following the ADR were examined and the outcomes were compared between different treatment groups.Results: Among 1 564 687 statin users, 19 035 (1.22%) had a statin-related ADR consultation in primary care. The mean (standard deviation) follow-up time was 6.32 (3.74) years and 5.31 (3.83) years for CVD primary and secondary prevention cohorts, respectively. Statin-related ADR consultation was associated with subsequent CVD events in both cohorts (adjusted hazard ratio [HR] of 1.39 [95% CI 1.23, 1.57] and 1.34 [95% CI 1.25,1.42], respectively). In the secondary analysis among patients with statin-related ADR consultation, we found that (i) continued statin prescription or combination of any statin with additional lipid-lowering treatment (LLT) and (ii) other LLT only were associated with lower risks of CVD event (adjusted HR 0.71 [95% CI 0.64, 0.78] and 0.75 [95% CI 0.62, 0.92], respectively) and all-cause mortality (adjusted HR 0.46 [95% CI 0.42, 0.50] and 0.52 [95% CI, 0.43, 0.64], respectively), compared to discontinuation of all LLT.

show abstract

“…[4][5][6][7][8] Lacking standardization has resulted in non-scientific diagnosis and management of statin intolerance in clinical practice and, at times, an overestimation of statin intolerance. 9,10 Multiple studies suggest that the statin usage rate and the lipid target achievement rate in the Chinese population are significantly lower than those in developed countries. This discrepancy is attributed to patients' concerns about statin-related adverse reactions and the inconsistent diagnosis and management of statin intolerance by clinical practitioners.…”

mentioning

confidence: 99%

Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance

Li,

Dou,

Zhou

et al. 2024

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The clinical benefits of statins have well‐established and recognized worldwide. Although statins are well‐tolerated generally, however, the report of statin‐related adverse event and statin intolerance are common in China, which results in insufficient use of statins and poor adherence. The main reason may be attributed to confusions or misconceptions in the clinical diagnosis and management in China, including the lack of unified definitions and diagnostic standards, broad grasp of diagnosis, and unscientific management strategies. Based on that, this consensus carefully summarized the statin‐related gene polymorphism and statin usage issue among Chinese population, and comprehensively reviewed global research data on statin intolerance, referenced guidelines, and consensus literature on statin intolerance in foreign and different regions, proposes an appropriate and easy to implement statin intolerance definition as well as corresponding diagnostic criteria and management strategies for Chinese clinicians, in order to improve the clinical application of statin drugs and enhance the prevention and treatment level of atherosclerotic cardiovascular disease in China.

show abstract

Predictors of a successful statin reattempt after an adverse reaction

Cited by 7 publications

References 39 publications

Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media

Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media

Statin‐related adverse drug reactions in UK primary care consultations: A retrospective cohort study to evaluate the risk of cardiovascular events and all‐cause mortality

Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance

Contact Info

Product

Resources

About